UC Davis — Research on Antiviral Drugs (Koen Van Rompay)

Organization Name 
Award Date 
3/2020
Grant Amount 
$206,613
Purpose 
To support a trial led by Koen Van Rompay of an HSP90 inhibitor as a possible treatment for Zika infections in rhesus macaque monkeys.
Topic (focus area) 

Grant Investigators: Chris Somerville and Heather Youngs

This page was reviewed but not written by the grant investigators. UC Davis staff also reviewed this page prior to publication.

Open Philanthropy recommended a grant of $206,613 to UC Davis to support a trial led by Koen Van Rompay of an HSP90 inhibitor as a possible treatment for Zika infections in rhesus macaque monkeys. The results of the trial could have implications for the use of HSP90 inhibitors as antiviral treatments in humans. This funding is part of our science team’s effort to explore chaperone inhibitors as broad spectrum, host-directed antiviral drugs.

This falls within our work on scientific research, specifically within our interest in science supporting biosecurity and pandemic preparedness.

The grant amount was updated in June 2020.